Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:March 1, 2018Completed
Hide Studies Not Open or Pending
Condition(s):Multiple MyelomaLast Updated:March 1, 2018Completed
Condition(s):Prostate CancerLast Updated:May 14, 2018Completed
Condition(s):Acute Myelogenous LeukemiaLast Updated:September 29, 2010Completed
Condition(s):Leukemia; Acute Lymphocytic LeukemiaLast Updated:May 21, 2018Withdrawn
Condition(s):Multiple MyelomaLast Updated:March 4, 2015Withdrawn
Condition(s):Mantle-Cell LymphomaLast Updated:July 15, 2015Terminated
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:August 22, 2023Completed
Condition(s):Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Bladder Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Stage III Bladder Cancer; Stage III Urethral Cancer; Stage IV Bladder Cancer; Stage IV Urethral Cancer; Transitional Cell Carcinoma of the Bladder; Ureter CancerLast Updated:June 5, 2013Completed
Condition(s):Multiple MyelomaLast Updated:April 30, 2021Completed
Condition(s):Chronic Myeloproliferative Disorders; LeukemiaLast Updated:October 17, 2014Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.